Monday, 16 November 2026Follow on 𝕏
Deals

AstraZeneca made $10bn offer for obesity drugmaker Rhythm, sources say

AstraZeneca (AZN) made an offer of about $10bn to acquire obesity drugmaker Rhythm Pharmaceuticals (RYTM), according to three people familiar with the matter.

The non-binding proposal valued Rhythm at as much as $134 a share, including payments tied to milestones, the people said. The Wall Street Journal reported that AstraZeneca had made a $124-per-share offer for the company last month.

Rhythm’s shares closed up 28 percent at $110.68 on the news, giving it a market capitalization of about $7.64bn.

Two of the people said the deal would be pursued through Alexion, AstraZeneca’s rare-disease business, which it acquired for $39bn in 2021 to expand beyond its core oncology and biopharmaceutical franchises. Alexion specializes in treatments for rare diseases and has become the centerpiece of the group’s push into high-growth specialty medicines. Rhythm develops therapies for rare neuroendocrine and metabolic disorders, including severe obesity. An AstraZeneca spokesperson declined to comment, and Rhythm did not respond to a request for comment.

The approach comes as chief executive Pascal Soriot seeks to shift investors’ focus back to growth after a turbulent few months. AstraZeneca, which has a market value of $292bn, has faced clinical trial setbacks, while reports of a potentially transformative deal with US rival Bristol Myers Squibb (BMY) weighed on its shares.

Jefferies analyst Michael Leuchten said AstraZeneca’s approach of seeking rare-disease assets that fit its “existing footprint is entirely sensible.” The Wall Street Journal reported that AstraZeneca had previously expressed interest in Rhythm and renewed its pursuit in recent months.

In March, the US Food and Drug Administration expanded the approved use of Rhythm’s therapy, Imcivree, to a rare form of obesity caused by brain damage, making it the first treatment cleared in the country for the condition. Leuchten said the company could historically be viewed as addressing ultra-rare genetic obesity, but that the approval in acquired hypothalamic obesity “materially changes that proposition.” Rhythm is also developing treatments for other rare neuroendocrine and metabolic diseases.

The obesity drug market has become one of the industry’s most coveted sectors, driven by strong demand for treatments from Novo Nordisk (NVO) and Eli Lilly (LLY), and by expectations that sales could exceed $100bn annually over the next decade. Rhythm’s therapies target rare genetic forms of obesity rather than the broader weight-loss market, but an acquisition would give AstraZeneca an established commercial presence in the fast-growing field while expanding its rare-disease portfolio.

AsCompany profileAstraZenecaKey facts and frequently asked questions